title: [Infliximab therapy for Crohn's disease - a practical guideline: actualised consensus of the working group for chronic inflammatory bowel diseases of the Austrian Society for Gastroenterology and Hepatology].
abstract: Infliximab is a monoclonal antibody against tumor necrosis factor alpha (TNF-α), which is approved for the treatment of chronic inflammatory bowel disease (IBD) such as Crohn's disease (CD), fistulating Crohn's disease (FCD), ulcerative colitis (UC), and paediatric ulcerative colitis (PUC) from 6 years onwards. Besides its therapeutic efficacy, this antibody therapy is characterised by its side effects profile, which has been addressed in a seperate consensus statement by the Working Group for chronic inflammatory bowel diseases within the Austrian Society for Gastroenterology and Hepatology. Infliximab is an effective treatment option for the above-mentioned indications; however, use of this agent requires special knowledge to assess the benefit-risk profile for each patient individually.
authors: AKH Wien, Univ.-Klinik für Innere Medizin III, Klin. Abteilung f. Gastroenterologie und Hepatologie, Wien, Österreich. walter.reinisch@meduniwien.ac.at
authors: W
authors: W
authors: Reinisch
authors: C
authors: C
authors: Dejaco
authors: T
authors: T
authors: Feichtenschlager
authors: T
authors: T
authors: Haas
authors: A
authors: A
authors: Kaser
authors: W
authors: W
authors: Miehsler
authors: G
authors: G
authors: Novacek
authors: W
authors: W
authors: Petritsch
authors: R
authors: R
authors: Platzer
authors: H
authors: H
authors: Tilg
authors: H
authors: H
authors: Vogelsang
authors: P
authors: P
authors: Knoflach
mesh_terms: D000893:Anti-Inflammatory Agents / Q000627:therapeutic use*; D000911:Antibodies, Monoclonal / Q000009:adverse effects / Q000627:therapeutic use*; D003424:Crohn Disease / Q000188:drug therapy*; D005762:Gastroenterology / Q000592:standards*; D005765:Gastrointestinal Agents / Q000627:therapeutic use; D005858:Germany; D006801:Humans; D000069285:Infliximab; D017410:Practice Guidelines as Topic
chemical_list: D000893:Anti-Inflammatory Agents; D000911:Antibodies, Monoclonal; D005765:Gastrointestinal Agents; D000069285:Infliximab